

**SESSION 1: ROLE AND IMPACT OF QUANTITATIVE SCIENCES IN
STRATEGIC DECISION MAKING**

**LEADERS
SURVEY RESULTS**

SURVEY RESULTS: WHO ARE WE?


~40% Big Pharma; ~40% Small/Mid-Size Pharma; ~20% other

~70% 10,000+; <5% Under 200

Scope of the functional support


Full question: Scope of the functional support. Please select all that apply.

Category	N	Percent of all	Percent of responders
Research/Pre-clinical	12	38.7	40.0
Manufacturing	7	22.6	23.3
Early Development	21	67.7	70.0
Full Development	26	83.9	86.7
Launch and life cycle (e.g., GMA, RWE, HEOR, etc...)	27	87.1	90.0




OUR ROLES IN DECISION MAKING


WHO?




HOW?



STRONGEST IN CLINICAL DEVELOPMENT DECISIONS; EMERGING IN PORTFOLIO, ORGANIZATION





Most common:

- Probability of Success
- Ad-hoc tables & figures
- Decision Criteria & Rules

Potential emerging areas:

- Scenario analyses
- Decision frameworks
- Visualization?

WHAT ARE THE ENABLERS & HURDLES FOR INVOLVEMENT IN DECISION MAKING?

ENABLERS

1. Reputation & Trust (22)
2. Communication Skills (12)
3. Company Mindset (11)
4. Business Context (10)
5. Visibility (8)

HURDLES

1. Communication Styles & Skills (24)
2. Organizational Willingness & Structures (23)
3. Perceptions (21)
4. Budgets, Resources & Planning (8)